Name & Company Information Location Interests
409921

Khalil Abdur-Rashid

Harvard University

Muslim Chaplain

contact_8300

Edward Abrahams, PhD

Personalized Medicine Coalition

President

Washington

District Of Columbia

United States

bio2018-mybio-icons-attendees

Dr. Mitch Abrahamsen

Acceligen

Chief Scientific & Commercialization Officer

St. Paul

Minnesota                  

United States

356283

Mr. Michael Abrams

Numerof & Associates, Inc.

Managing Partner

Saint Louis

Missouri

United States

356330

Mr. Michael Adatto

Ferring

AVP, Market Access

Parsippany

New Jersey

United States

414319

Dr. Isaac Adewole

Nigeria

Minister of Health and Oncologist

356149

Mr. Amos Adler, MBA,MSc

Memotext Corporation, A4i

CEO

Toronto

Ontario

Canada

Academic/Non-Profit>Foundation/Patient Advocacy, Academic/Non-Profit>Tech Transfer, Diagnostics/Device/Digital Health>Patient Monitoring Device, Interest Area>Digital Health, Interest Area>Mental Health, Interest Area>Regulatory Innovation, Interest Area>Value, Investor>Angel Or Family Office, Product Focus Zone/Special Pavilion>Patient Advocacy Pavilion, Research Tools/Support>Bioinformatics, Research Tools/Support>Digital Health, Service>CRO & Analytical Labs, Service>Consulting, Session Tracks>Digital Health, Session Tracks>Translational Research
414306

Prof. Innocent Adoubi

Côte d'Ivoire

National Cancer Director

bio2018-mybio-icons-attendees

Mukul Agarwal

Revance

Vice President

San Francisco

California                  

United States

357520

Marcello Agosti

Takeda Pharmaceuticals

Head of Global Business Development

Deerfield

Deerfield

United States

394036

Hon. Jorge Aguado

Argentina

Vice Minister

423645

Jennifer Ahlstrom

CrowdCare Foundation

President and Co-Founder

bio2018-mybio-icons-attendees

Ram Aiyar

Cordiva Therapuetics

EVP Corporate and Business Development

San Francisco

California                  

United States

355843

Mr. John Alam, ACHA

EIP Pharma

CEO

Cambridge

Massachusetts

United States

bio2018-mybio-icons-attendees

Morgen Alden

LifeSci Advisors

Director of Key Opinion Leader (KOL) Strategy and Management

356179

Ms. Meg Alexander

Syneos Health

Head, Reputation and Risk Management Practice

New York

New York

United States

388198

Kevin Ali

Merck & Co, Inc.

President, MSD International

Whitehouse Station

NJ

United States

416510

Albert Allen

Eli Lilly and Company

Senior Medical Fellow, Bioethics & Pediatric Capabilities

Academic/Non-Profit>Foundation/Patient Advocacy, Academic/Non-Profit>University (Faculty), Drug>Clinical, Drug>Preclinical, Interest Area>CNS/Neurological, Interest Area>Mental Health, Interest Area>Next Generation Bioetherapeutics, Interest Area>Oncology, Interest Area>Orphan & Rare Diseases, Interest Area>Pain Management, Interest Area>Patient Access & Reimbursement, Interest Area>Personalized Medicine & Diagnostics, Interest Area>Preclinical/Research, Interest Area>Regulatory Innovation, Interest Area>Regulatory Science, Interest Area>Research Tools, Interest Area>Translational Research, Session Tracks>Next Generation Biotherapeutics, Session Tracks>Oncology, Session Tracks>Orphan & Rare Diseases, Session Tracks>Personalized Medicine & Diagnostics, Session Tracks>Regulatory Innovation, Session Tracks>Translational Research
401550

Debbie Allen

argenx

Senior Vice President Business Development

Gent

Gent

Belgium

399179

Mr. Matthew Allen, CSP

Cabot Corportation

Director of Process Safety (Global)

Billerica

Massachusetts

United States

421342

James Allison, PhD

MD Anderson Cancer Center

Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research

355809

Mr. Gregg Alton

Gilead

EVP for International Operations and Corporate Affairs

Foster City, CA

Foster City, CA

United States

395419

Dr. Michael Altorfer

Swiss Biotech Association

CEO

Zürich

Zürich

Switzerland

401937

Sam Alworth, MPA,MS

AcuraStem Inc.

CEO

Monrovia, CA

Monrovia, CA

United States

Academic/Non-Profit>Incubator/Technology Park, Drug>Preclinical, Interest Area>Bioinformatics, Interest Area>Brain Health, Interest Area>CNS/Neurological, Interest Area>Central Nervous System, Interest Area>Mental Health, Interest Area>Neurological Disease, Interest Area>Orphan & Rare Diseases, Interest Area>Personalized Medicine & Diagnostics, Investor>Angel Or Family Office, Investor>Hedge Fund/Mutual Fund, Investor>VC/PE, Research Tools/Support>Bioinformatics, Research Tools/Support>Instrumentation, Service>CRO & Analytical Labs, Service>Consulting, Service>Investment Banking Or Lending, Session Tracks>Brain Health, Session Tracks>Genome Editing, Session Tracks>Orphan & Rare Diseases, Session Tracks>Personalized Medicine & Diagnostics, Session Tracks>Value‚ Patient Access‚ & Reimbursement
416407

Katherine Andersen

Silicon Valley Bank

Head of Healthcare Corporate Finance and East/Central Life Science

Boston

MA

United States

407238

Daniel Anderson

InVitae Corporation

Head of Commercial Partnerships

San Francisco

San Francisco

United States

Academic/Non-Profit>Foundation/Patient Advocacy, Drug>Clinical, Drug>Market - Drug (on Patent), Drug>Preclinical, Interest Area>Business Development & Finance, Interest Area>CNS/Neurological, Interest Area>Gene Editing, Interest Area>Gene/Cell Therapy, Interest Area>Genetic Disorders, Interest Area>Genomics, Interest Area>Metabolic Diseases, Interest Area>Molecular Diagnostics, Interest Area>Neurological Disease, Interest Area>Oncology, Interest Area>Orphan & Rare Diseases, Interest Area>Partnering, Interest Area>Pharmacogenomics, Interest Area>Proteomics, Interest Area>Regulatory Innovation, Interest Area>Therapeutics, Session Tracks>Business Development & Finance, Session Tracks>Genome Editing, Session Tracks>Next Generation Biotherapeutics, Session Tracks>Oncology, Session Tracks>Orphan & Rare Diseases, Session Tracks>Regulatory Innovation
414636

Margaret Anderson

Deloitte Consulting LLP

Managing Director

412088

Jane Andrews

Wegmans Food Markets

Corporate Nutrition Manager

409879

Richard Andrews

Azitra, Inc.

President & CEO

Farmington

CT

United States

382488

Mr. William Annett

OncoCyte Corporation

Chief Executive Officer

Alameda

Alameda

United States

405178

Dr. Patrick Anquetil

Portal Instruments

CEO

Cambridge

Cambridge

United States

409300

Karen Antebi

Embassy of Mexico in Washington

Economic Counselor for the Trade & NAFTA Office

Washington

DC

United States

401539

Anjan Aralihalli

GLyPharma Therapeutic; CTI Life Sciences Fund II

Chief Business Officer; Venture Partner

MOntreal

Quebec

Canada

357683

Robert Armstrong, PhD

Boston Pharmaceuticals

Chief Executive Officer

Cambridge

Cambridge

United States

image_preview

Dr. Stephen Arnerić

Critical Path Institute

Executive Director, CPAD; Professor of Research, University of Arizona

Tucson

Tucson

United States

Charlie Arnot biz 2011

Mr. Charlie Arnot

The Center for Food Integrity

CEO

Gladstone

Missouri                      

United States

IMG_6210

Ms. Kathleen Arntsen, BA

Lupus & Alied Diseases Association

President & CEO

Verona

New York                    

United States

392828

Mr. David Arthur

Salarius Pharmaceuticals LLC

CEO

Houston

Houston

United States

userPhoto

Phyllis Arthur

Biotechnology Innovation Organization (BIO)

Vice President, Infectious Diseases & Diagnostics Policy

Washington

District Of Columbia

United States

Diagnostics/Device/Digital Health>Molecular/Cellular Diagnostics, Drug>Clinical, Drug>Market - Drug (on Patent), Interest Area>Emerging Opportunities In Global Markets, Interest Area>Gene Editing, Interest Area>Gene/Cell Therapy, Interest Area>Immunology, Interest Area>Infectious Diseases & Vaccines, Interest Area>Molecular Diagnostics, Interest Area>Personalized Medicine & Diagnostics, Interest Area>Regenerative Medicine, Interest Area>Value, Investor>VC/PE, Session Tracks>Emerging Opportunities In Global Markets, Session Tracks>Genome Editing, Session Tracks>Infectious Diseases & Vaccines, Session Tracks>Personalized Medicine & Diagnostics
0

Dr. Akwasi A Asabere, PhD.

Helix

Business Development & Partnerships

San Carlos

California

United States

bio2018-mybio-icons-attendees

Anil Asnani

LabCorp

Head of M&A

North Carolina

North Carolina

United States

bio2018-mybio-icons-attendees

Dr. David Atuwo

Ministry of Health of Nigeria

National Cancer Control Coordinator

389752

Paldeep Atwal, FRCP,MD

Genome Medical

Geneticist

Jacksonville

Florida

United States

357401

Ms. Regina Au, MBA,MIM

BioMarketing Insight

Principal, New Product Planning/Strategic Commercialization

Woburn

Massachusetts

United States

Interest Area>Bioinformatics, Interest Area>Biologics, Interest Area>CNS/Neurological, Interest Area>Corporate Best Practices & Leadership, Interest Area>Diagnostics, Interest Area>Digital Health, Interest Area>Emerging Opportunities In Global Markets, Interest Area>Gene Editing, Interest Area>Genetic Disorders, Interest Area>Genomics, Interest Area>Imaging, Interest Area>Immunology, Interest Area>Infectious Diseases & Vaccines, Interest Area>Medical Devices, Interest Area>Metabolic Diseases, Interest Area>Molecular Diagnostics, Interest Area>Neurological Disease, Interest Area>Next Generation Bioetherapeutics, Interest Area>Non-Profit/Patient Advocacy Group, Interest Area>Orphan & Rare Diseases, Interest Area>Patient Access & Reimbursement, Interest Area>Regenerative Medicine, Interest Area>Regulatory Innovation, Interest Area>Stem Cell Research, Interest Area>Tissue Engineering, Interest Area>Translational Research, Interest Area>Value, Investor>Angel Or Family Office, Investor>VC/PE, Session Tracks>Brain Health, Session Tracks>Business Development & Finance, Session Tracks>Corporate Best Practices & Leadership, Session Tracks>Digital Health, Session Tracks>Emerging Opportunities In Global Markets, Session Tracks>Genome Editing, Session Tracks>Infectious Diseases & Vaccines, Session Tracks>Next Generation Biotherapeutics, Session Tracks>Oncology, Session Tracks>Orphan & Rare Diseases, Session Tracks>Personalized Medicine & Diagnostics, Session Tracks>Regulatory Innovation, Session Tracks>Translational Research, Session Tracks>Value‚ Patient Access‚ & Reimbursement
357337

Dr. Jared Auclair

Northeastern University

Director of Executive Training and Biotechnology Programs

Boston

Massachusetts

United States

Academic/Non-Profit>Incubator/Technology Park, Academic/Non-Profit>Research Institute, Academic/Non-Profit>University (Faculty), Diagnostics/Device/Digital Health>Drug Delivery Device, Diagnostics/Device/Digital Health>Molecular/Cellular Diagnostics, Diagnostics/Device/Digital Health>Non Drug Delivery Device, Diagnostics/Device/Digital Health>Non-Molecular Diagnostics, Diagnostics/Device/Digital Health>Patient Monitoring Device, Drug>Clinical, Drug>Market - Drug (on Patent), Drug>Preclinical, Interest Area>Bioinformatics, Interest Area>Biologics, Interest Area>Biomanufacturing, Interest Area>CNS/Neurological, Interest Area>Cell Biology, Interest Area>Central Nervous System, Interest Area>Diagnostics, Interest Area>Drug Delivery, Interest Area>Emerging Opportunities In Global Markets, Interest Area>Gene Editing, Interest Area>Gene/Cell Therapy, Interest Area>Genetic Disorders, Interest Area>Genetically-enhanced Microbes, Interest Area>Genomics, Interest Area>Immunology, Interest Area>Medical Devices, Interest Area>Neurological Disease, Interest Area>Oncology, Interest Area>Orphan & Rare Diseases, Interest Area>Personalized Medicine & Diagnostics, Interest Area>Proteomics, Interest Area>Regenerative Medicine, Interest Area>Regulatory Innovation, Interest Area>Regulatory Science, Interest Area>Small Molecules, Interest Area>Stem Cell Research, Interest Area>Therapeutics, Interest Area>Tissue Engineering, Interest Area>Translational Research, Research Tools/Support>Bioinformatics, Research Tools/Support>Instrumentation, Research Tools/Support>Research Technology, Service>CRO & Analytical Labs, Service>Consulting, Session Tracks>Brain Health, Session Tracks>Genome Editing, Session Tracks>Infectious Diseases & Vaccines, Session Tracks>Intellectual Property, Session Tracks>Next Generation Biotherapeutics, Session Tracks>Oncology, Session Tracks>Orphan & Rare Diseases, Session Tracks>Personalized Medicine & Diagnostics, Session Tracks>Regulatory Innovation, Session Tracks>Translational Research
415906

Dr. William Audeh

AGENDIA

Chief Medical Officer

391494

Bobbie Ann Austin, PhD

National Institutes of Health

Program Officer

Bethesda

Maryland

United States

394651

Dr. Christopher P. Austin, MD

National Institutes of Health

Director, National Center for Advancing Translational Sciences

358112

Mr. Mark Avagliano

Pfizer

VP, Corporate Development

New York

New York

United States

406675

Divya Babin

Theravectys

Senior VP, Business Development

Cambridge

Cambridge

United States